Compare Nasdaq100 ETF (QQQ) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nasdaq100 ETF vs Sanofi SA — how do they compare? Nasdaq100 ETF trades at $717.23, while Sanofi SA trades at $42.7 (market cap $104.06B). The key difference: Sanofi SA pays a 5.61% dividend while Nasdaq100 ETF pays none, and Nasdaq100 ETF is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| QQQ | SNY | |
|---|---|---|
52-Week High | $746.16 | $52.34 |
52-Week Low | $558.34 | $41.33 |
Market Cap | — | $104.06B |
Sector | — | Health |
Enterprise Value | — | $124.09B |
Dividend Yield | — | 5.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QQQ trades at $718.36, showing minimal daily movement with a slight decline of 0.08%. Technical indicators signal a bullish trend with strong moving average support, while oscillators remain neutral. The ETF maintains its position as a leading Nasdaq-100 tracker, though financial ratios are not applicable for this index fund structure. Recent news highlights ongoing institutional interest and comparisons with competing funds.
The outlook remains positive given the bullish technical setup and strong institutional backing. However, investors face risks from market volatility and fee structure comparisons with competing funds. The divided analyst consensus reflects uncertainty about near-term performance despite the fund's long-term growth trajectory.
Sanofi (SNY) trades at $43.155, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported strong Q2 2026 earnings, beating expectations with EPS of $1.21 versus $1.10 expected, and raised full-year guidance. Recent FDA approvals for COVID vaccines and EU approval for MenQuadfi in infants provide positive catalysts, though pipeline setbacks with an eczema drug withdrawal create uncertainty.
SNY presents a mixed outlook with solid fundamentals including a 5.4% dividend yield and reasonable valuation (P/E 22.94), but faces execution risks under new CEO leadership. Analyst consensus leans Hold (51.86%) with price target of $49.50, suggesting moderate upside potential. Key risks include drug pipeline challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nasdaq100 ETF
The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on QQQ →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
